Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Capital Expenditures of $434000.0 for Q1 2026, down 7.07% year-over-year from $467000.0 in Q1 2025, and down 92.54% quarter-over-quarter from $5.8 million in Q4 2025.
Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Capital Expenditures for 8 consecutive years, with $434000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 7.07% year-over-year to $434000.0; the TTM figure through Mar 2026 stood at $7.1 million (up 20.8% YoY), while the FY2025 annual figure was $7.2 million, down 44.2% from the prior year.
- Capital Expenditures retreated to $434000.0 in Q1 2026 per KYMR's latest filing, from $5.8 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $10.8 million in Q2 2023 and bottomed at -$14.8 million in Q3 2023.
- Historically, Capital Expenditures has averaged $1.2 million across 5 years, with a median of $695000.0 in 2025.
- On a YoY basis, Capital Expenditures climbed as much as 1365.03% in 2023 and fell as far as 1285.96% in 2023.
- Kymera Therapeutics' Capital Expenditures stood at -$1.5 million in 2022, then soared by 37.95% to -$909000.0 in 2023, then surged by 202.97% to $936000.0 in 2024, then soared by 521.9% to $5.8 million in 2025, then plunged by 92.54% to $434000.0 in 2026.
- Business Quant data shows KYMR's Capital Expenditures at $434000.0 in Q1 2026, $5.8 million in Q4 2025, and $181000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -2.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.16 Mn |
| Jun 30, 2026 | -2.16 Mn |
| Mar 31, 2026 | 434,000.00 |
| Mar 31, 2026 | 434,000.00 |
| Dec 31, 2025 | 5.82 Mn |
| Dec 31, 2025 | 5.82 Mn |
| Sep 30, 2025 | 181,000.00 |
| Sep 30, 2025 | 181,000.00 |
| Jun 30, 2025 | 695,000.00 |
| Jun 30, 2025 | 695,000.00 |
| Mar 31, 2025 | 467,000.00 |
| Mar 31, 2025 | 467,000.00 |
| Dec 31, 2024 | 936,000.00 |
| Dec 31, 2024 | 936,000.00 |
| Sep 30, 2024 | -189,000.00 |
| Sep 30, 2024 | -189,000.00 |
| Jun 30, 2024 | 4.69 Mn |
| Jun 30, 2024 | 4.69 Mn |
| Mar 31, 2024 | 7.40 Mn |
| Mar 31, 2024 | 7.40 Mn |